Study identification

PURI

https://redirect.ema.europa.eu/resource/50487

EU PAS number

EUPAS40706

Study ID

50487

Official title and acronym

A Retrospective Cohort Study to Characterize Patient Characteristics and Treatment Outcomes Among Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database (20190402)

DARWIN EU® study

No

Study countries

France

Study description

A retrospective cohort study of locally advanced or metastatic non-small cell lung cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database. The source population in ESME-AMLC database includes adult patients who initiate lung cancer treatment (radiotherapy, chemotherapy, targeted therapy and immunotherapy) or diagnosed with metastatic cancer in a participating medical center. Patients aged 18 and over at the time of NSCLC diagnosis, with diagnosis of locally advanced or metastatic NSCLC between 1 Jan 2015 - 30 Jun 2022 will be included. Data on patients will be collected from date of initial NSCLC diagnosis until death or date of last contact, whichever occurs first.

Study status

Ongoing
Research institution and networks

Institutions

Unicancer
France
First published:
22/11/2024
InstitutionLaboratory/Research/Testing facilityNot-for-profit

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable